Marker Therapeutics Valuation
| MRKR Stock | USD 3.26 0.07 2.10% |
At this time, the firm appears to be overvalued. Marker Therapeutics secures a last-minute Real Value of $2.85 per share. The latest price of the firm is $3.26. Our model forecasts the value of Marker Therapeutics from analyzing the firm fundamentals such as Current Valuation of 11.59 M, profit margin of (2.78) %, and Return On Equity of -0.72 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Marker Therapeutics' valuation include:
Price Book 3.9888 | Enterprise Value 11.6 M | Enterprise Value Ebitda (0.22) | Price Sales 7.8044 | Enterprise Value Revenue 3.4122 |
Overvalued
Today
Please note that Marker Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Marker Therapeutics is based on 3 months time horizon. Increasing Marker Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Marker stock is determined by what a typical buyer is willing to pay for full or partial control of Marker Therapeutics. Since Marker Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Marker Stock. However, Marker Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.26 | Real 2.85 | Target 40.0 | Hype 3.26 | Naive 3.52 |
The intrinsic value of Marker Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Marker Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Marker Therapeutics helps investors to forecast how Marker stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Marker Therapeutics more accurately as focusing exclusively on Marker Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Marker Therapeutics' intrinsic value based on its ongoing forecasts of Marker Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Marker Therapeutics' closest peers.
Marker Therapeutics Cash |
|
Marker Valuation Trend
Marker Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Marker Therapeutics' financial worth over time. Using both Marker Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Marker Therapeutics Total Value Analysis
Marker Therapeutics is now forecasted to have valuation of 11.59 M with market capitalization of 29.09 M, debt of 3.07 M, and cash on hands of 18.08 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Marker Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.59 M | 29.09 M | 3.07 M | 18.08 M |
Marker Therapeutics Investor Information
About 12.0% of the company outstanding shares are owned by corporate insiders. The book value of Marker Therapeutics was now reported as 1.58. The company recorded a loss per share of 1.07. Marker Therapeutics last dividend was issued on the 16th of September 2016. The entity had 1:10 split on the 27th of January 2023. Based on the key indicators related to Marker Therapeutics' liquidity, profitability, solvency, and operating efficiency, Marker Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Marker Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Marker Therapeutics has an asset utilization ratio of 19.33 percent. This connotes that the Company is making $0.19 for each dollar of assets. An increasing asset utilization means that Marker Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Marker Therapeutics Ownership Allocation
The market capitalization of Marker Therapeutics is $29.09 Million. Marker Therapeutics secures 12.19 % of its outstanding shares held by insiders and 22.44 % owned by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Marker Therapeutics Profitability Analysis
The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (17.13 M).About Marker Therapeutics Valuation
The stock valuation mechanism determines Marker Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Marker Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Marker Therapeutics. We calculate exposure to Marker Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Marker Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -7.1 M | -6.8 M | |
| Pretax Profit Margin | (4.24) | (4.45) | |
| Operating Profit Margin | (4.40) | (4.62) | |
| Net Loss | (4.24) | (4.45) | |
| Gross Profit Margin | (2.15) | (2.25) |
Marker Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Marker Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 8.8 M |
Marker Therapeutics Current Valuation Indicators
Marker Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Marker Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Marker Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Marker Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Marker Therapeutics' worth.Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.